BMS-955176 is an experimental second generation
HIV
The human immunodeficiency viruses (HIV) are two species of '' Lentivirus'' (a subgroup of retrovirus) that infect humans. Over time, they cause acquired immunodeficiency syndrome (AIDS), a condition in which progressive failure of the immu ...
maturation inhibitor under
development by
Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells. First generation maturation inhibitors such as
bevirimat were ineffective against some naturally occurring changes (polymorphisms) in the
Gag protease
HIV-1 protease (PR) is a retroviral aspartyl protease (retropepsin), an enzyme involved with peptide bond hydrolysis in retroviruses, that is essential for the life-cycle of HIV, the retrovirus that causes AIDS. HIV protease cleaves newly synthe ...
polyprotein; BMS-955176 has been selected to better tolerate gag
polymorphisms.
__TOC__
Studies
Results of a
phase 2a trial of BMS-955176 was reported at the 2015
Conference on Retroviruses and Opportunistic Infections (CROI).
Investigators concluded that the drug was well tolerated and effective against HIV, including strains with gag polymorphisms.
Phase 2b studies are currently ongoing in early 2016. It appears that development of BMS-955176 has been terminated.
See also
*
Fipravirimat
References
{{HIVpharm
Antiretroviral drugs
Maturation inhibitors
Experimental drugs